Cargando…

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia

Detalles Bibliográficos
Autores principales:	La Starza, Roberta, Cambò, Benedetta, Pierini, Antonio, Bornhauser, Beat, Montanaro, Anna, Bourquin, Jean-Pierre, Mecucci, Cristina, Roti, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448796/ https://www.ncbi.nlm.nih.gov/pubmed/32923866 http://dx.doi.org/10.1200/PO.19.00172

Ejemplares similares

T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness
por: Bardelli, Valentina, et al.
Publicado: (2021)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

PB1736: CLINICAL ANALYSIS OF VENETOCLAX-BASED IN THE TREATMENT OF ADULT RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Jing, et al.
Publicado: (2023)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
por: Stanulla, Martin, et al.
Publicado: (2023)

Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin
por: La Starza, Roberta, et al.
Publicado: (2018)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
por: Niswander, Lisa M., et al.
Publicado: (2023)

Erythroleukemia Relapsing as Precursor B-cell Lymphoblastic Leukemia
por: Park, Borae G., et al.
Publicado: (2011)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults
por: Arniani, Silvia, et al.
Publicado: (2022)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Stein, Anthony, et al.
Publicado: (2018)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
por: Mezzatesta, Caterina, et al.
Publicado: (2019)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
por: Labrador, Jorge, et al.
Publicado: (2022)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
por: Piccini, Matteo, et al.
Publicado: (2023)

Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom
por: Aristides, Mike, et al.
Publicado: (2015)

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors
por: Erarslan‐Uysal, Büşra, et al.
Publicado: (2020)

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
por: Seyfried, Felix, et al.
Publicado: (2019)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia
por: Montanaro, Anna, et al.
Publicado: (2022)

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
por: Cerrano, Marco, et al.
Publicado: (2022)

Efficacy of Low Dose Clofarabine in Refractory Precursor T- Acute Lymphoblastic Leukemia
por: Choi, Jaehyuk, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_572pv7roshti64h06cct1571c3